Clinical Trials Logo

Chronic Ischemic Stroke clinical trials

View clinical trials related to Chronic Ischemic Stroke.

Filter by:
  • None
  • Page 1

NCT ID: NCT06299033 Recruiting - Clinical trials for Chronic Ischemic Stroke

A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke

Start date: November 9, 2023
Phase: Phase 1
Study type: Interventional

The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects with stable chronic ischemic stroke.

NCT ID: NCT05694663 Recruiting - Clinical trials for Chronic Ischemic Stroke

Vagal Nerve Stimulation in Enhanced Stroke Recovery: The VALOR Registry

VALOR
Start date: November 1, 2022
Phase:
Study type: Observational [Patient Registry]

Vagal Nerve Stimulation is a novel proven therapy for patients with chronic ischemic stroke. The primary objective of this registry is to assess the safety of vagal nerve stimulation for stroke recovery through monitoring the occurrence of serious adverse events associated with the surgical procedure or subsequent paired rehabilitation protocol. This registry will monitor patients undergoing VNS for stroke recovery in the Mount Sinai Health System and collect clinical and procedural details, objective outcomes, and patient-reported outcomes associated with vagal nerve stimulation for stroke recovery.

NCT ID: NCT02448641 Completed - Clinical trials for Chronic Ischemic Stroke

Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

ACTIsSIMA
Start date: March 8, 2016
Phase: Phase 2
Study type: Interventional

Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke

NCT ID: NCT01287936 Completed - Clinical trials for Chronic Ischemic Stroke

A Study of Modified Stem Cells in Stable Ischemic Stroke

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.